Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies

Julie C Harper; April Armstrong; Richard G Fried; Evan A Rieder; Andrew F Alexis; Raidah J Salem; Ismail Kasujee; Ayman Grada

doi:10.1016/j.jaad.2023.04.075

Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies

J Am Acad Dermatol. 2023 Oct;89(4):832-834. doi: 10.1016/j.jaad.2023.04.075. Epub 2023 Jun 13.

Authors

Julie C Harper¹, April Armstrong², Richard G Fried³, Evan A Rieder⁴, Andrew F Alexis⁵, Raidah J Salem⁶, Ismail Kasujee⁷, Ayman Grada⁸

Affiliations

¹ Dermatology and Skin Care Center of Birmingham, Birmingham, Alabama.
² University of Southern California, Los Angeles, California.
³ Yardley Dermatology, Yardley, Pennsylvania.
⁴ Private Practice, New York, New York.
⁵ Weill Cornell Medicine, New York, New York.
⁶ Almirall, LLC, Malvern, Pennsylvania. Electronic address: raidah.salem@almirall.com.
⁷ Almirall, Barcelona, Spain.
⁸ Department of Dermatology, Case Western Reserve University School of Medicine, Health Education Campus, Cleveland, Ohio.

PMID: 37321481
DOI: 10.1016/j.jaad.2023.04.075

No abstract available

Keywords: Skindex-16; acne; dysbiosis; emotion; functioning; health-related quality of life; narrow-spectrum antibiotics; patient-reported outcomes; pediatric; sarecycline.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acne Vulgaris* / drug therapy
Anti-Bacterial Agents / therapeutic use
Clinical Trials, Phase III as Topic
Humans
Patient Reported Outcome Measures
Quality of Life
Tetracyclines*

Substances

Anti-Bacterial Agents
sarecycline
Tetracyclines